VC Catalog · venture ecosystem research library
VC Catalog home Beta

Company

Avere Therapeutics

Rocket Ship RatingBased on the data VC Catalog holds.

Rocket Ship Rating: 75 out of 100

Advancing Oral IL-23 Inhibition for Inflammatory Disease

  • Biotech & therapeutics
Status
Operatingas of 2026-09-18
Business model
B2B
Open relationship map
Claim, correct or request removal

Record updated 28 September 2026

About

Avere Therapeutics is developing AVR-001, an oral, once-weekly interleukin-23 receptor antagonist (IL-23RA) designed to deliver both convenience and competitive efficacy.

Products

Other
AVR-001
Loading relationship preview

Cookies on VC Catalog

We use necessary cookies to run the site (sign-in, security, remembering this choice). With your permission we also use Google Analytics to understand how the site is used. Analytics cookies are set only if you accept all cookies. Privacy policy